• EyePoint named Tarek S. Hassan as senior vice president, chief strategic science officer, reporting to CEO Jay S. Duker.
• Role targets strategy across the portfolio, including lead program DURAVYU, as Phase 3 wet AMD topline data nears.
• Hassan is a retina specialist with 35+ years’ experience, now a professor at Oakland University William Beaumont School of Medicine.
• He is also a senior partner at Associated Retinal Consultants, with experience across 180+ multicenter clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130700PRIMZONEFULLFEED9760599) on July 13, 2026, and is solely responsible for the information contained therein.